If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Area of Expertise

My research is focused on enhancing therapeutic efficacy in cancer. I have collaborated with Dr. Andras Lacko on the development of a lipoprotein-based targeted drug delivery vehicle for cancer chemotherapeutic agents. Also, I collaborate with Dr. Riyaz Basha in investigating the strategies to induce therapeutic efficacy of the chemotherapeutic agents used in standard care. We are investigating the effect of combination therapy of standard chemotherapeutic agents with clotum and Mithramicin for Ewing sarcoma, medulloblastoma, and neuroblastoma cell lines.

Education/Academic qualification

PhD in Chemistry, University of Kerala

MS in Applied Chemistry, Cochin University of Science and Technology

BS in Chemistry, University of Kerala

Fingerprint Dive into the research topics where Maya Nair is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Phosphatidylcholine-Sterol O-Acyltransferase Medicine & Life Sciences
HDL Lipoproteins Medicine & Life Sciences
Nanoparticles Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences
valrubicin Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Lipoproteins Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1997 2019

  • 613 Citations
  • 10 h-Index
  • 19 Article
  • 2 Review article
1 Citation (Scopus)
Open Access
Health
Aptitude
Translational Medical Research
Organized Financing
Self Efficacy

Ovarian cancer: Current status and strategies for improving therapeutic outcomes

Chandra, A., Pius, C., Nabeel, M., Nair, M., Vishwanatha, J. K., Ahmad, S. & Basha, R., 1 Nov 2019, In : Cancer Medicine. 8, 16, p. 7018-7031 14 p.

Research output: Contribution to journalReview article

Open Access
Ovarian Neoplasms
Platinum
Drug Therapy
Therapeutics
Survival Rate

Pancreatic cancer: An emphasis on current perspectives in immunotherapy

Patel, K., Siraj, S., Smith, C., Nair, M., Vishwanatha, J. K. & Basha, R., 1 Jan 2019, In : Critical Reviews in Oncogenesis. 24, 2, p. 105-118 14 p.

Research output: Contribution to journalArticle

Pancreatic Neoplasms
Immunotherapy
Neoplasms
Clinical Trials
Programmed Cell Death 1 Receptor
36 Citations (Scopus)

Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles

Sabnis, N., Nair, M., Israel, M., McConathy, W. J. & Lacko, A. G., 5 Dec 2012, In : International Journal of Nanomedicine. 7, p. 975-983 9 p.

Research output: Contribution to journalArticle

valrubicin
Lipoproteins
Encapsulation
Nanoparticles
Solubility
140 Citations (Scopus)

Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles

Shahzad, M. M. K., Mangala, L. S., Han, H. D., Lu, C., Bottsford-Miller, J., Nishimura, M., Mora, E. M., Lee, J. W., Stone, R. L., Pecot, C. V., Thanapprapasr, D., Roh, J. W., Gaur, P., Nair, M. P., Park, Y. Y., Sabnis, N., Deavers, M. T., Lee, J. S., Ellis, L. M., Lopez-Berestei, G. & 4 others, McConathy, W. J., Prokai, L., Lacko, A. G. & Sood, A. K., Apr 2011, In : Neoplasia. 13, 4, p. 309-319 11 p.

Research output: Contribution to journalArticle

HDL Lipoproteins
Nanoparticles
Small Interfering RNA
Scavenger Receptors
Neoplasms